Skip to main content


Table 2 Emerging targets clinical significance with ongoing clinical trials in RCC

From: Emerging therapeutic agents for genitourinary cancers

Molecular target Class Trial Disease setting Agent Experimental treatment Study phase Estimated completion
VEGF TKI NCT01253668 Previously-treated mRCC Brivanib Phase II Completed*
TGFβ NCT01806064 Previously-treated mRCC Endoglin Axitinib + endoglin Phase I/II June 2019
cMET NCT02761057 (PAPMET) Papillary mRCC Cabozantinib Cabozantinib S-malate Crizotinib Savolitinib Sunitinib Phase II January 2021
NCT03091192 MET-driven papillary mRCC Savolitinib Phase III August 2019
CCR4 Cytokine modulator NCT02281409 Advanced tumors (mRCC) Mogamulizumab Phase I/II October 2019
NCT02946671 Pre-operative advanced tumors (mRCC) Mogamulizumab Mogamulizumab + nivolumab Phase III March 2020
HIF2-α Small-molecule inhibitor NCT02293980 Previously-treated mRCC PT2385 PT238 monotherapy or PT2385 + nivolumab or PT2385 + cabozantinib Phase I August 2020
NCT03108066 VHL disease-associated ccRCC PT2385 Phase II September 2022
PD-L1 CPI NCT02420821 (IMmotion-151) Previously-untreated mRCC Atezolizumab Atezolizumab + bevacizumab Phase III December 2021
NCT02811861 (Keynote-581/CLEAR) Previously-untreated mRCC Pembrolizumab Pembrolizumab + lenvatinib Phase III February 2021
NCT03141177 (CheckMate 9ER) Previously-untreated mRCC Nivolumab Nivolumab + cabozantinib Phase III April 2023
NCT03149822 mRCC Pembrolizumab Pembrolizumab + cabozantinib Phase I/II June 2020
CTLA-4 NCT02762006 Previously-untreated localized RCC Neoadjuvant tremelimumab Neoadjuvant tremelimumab + durvalumab Phase I April 2019**
NCT02626130 Previously-treated mRCC Tremelimumab Tremelimumab or tremelimumab with cryoablation Pilot study March 2022
Autologous DCs Tumor vaccine NCT02432846 (MERECA) mRCC Intuvax Intuvax + nephrectomy+ sunitinib Phase II August 2019
  1. All trial information obtained through publicly accessible
  2. *Announcement of study results pending
  3. **Remains active